Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options?

× No keyword cloud information.

11 in total

1. Diabetes in a child on growth hormone therapy: Answers.

Authors: Melanie Aldridge; Tony Huynh; Jose Prado; Steven J McTaggart
Journal: Pediatr Nephrol Date: 2017-03-27 Impact factor: 3.714

Review 2. Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?

Authors: Bharti Balhara; Madhusmita Misra; Lynne L Levitsky
Journal: Indian J Pediatr Date: 2011-11-17 Impact factor: 1.967

Review 3. Progression of glomerular and tubular disease in pediatrics.

Authors: Robert P Woroniecki; H William Schnaper
Journal: Semin Nephrol Date: 2009-07 Impact factor: 5.299

4. Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress.

Authors: Subramanyam N Murthy; Sergiy Sukhanov; Jennifer McGee; Joel A Greco; Surabhi Chandra; Patrice Delafontaine; Philip J Kadowitz; Dennis B McNamara; Vivian A Fonseca
Journal: Mol Cell Biochem Date: 2009-04-10 Impact factor: 3.396

Review 5. Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors: Juan E Puche; Inma Castilla-Cortázar
Journal: J Transl Med Date: 2012-11-14 Impact factor: 5.531

6. Glucose lowering effect of transgenic human insulin-like growth factor-I from rice: in vitro and in vivo studies.

Authors: Stanley Ck Cheung; Li-Zhong Liu; Lin-Lin Lan; Qiao-Quan Liu; Samuel Sm Sun; Juliana Cn Chan; Peter Cy Tong
Journal: BMC Biotechnol Date: 2011-04-12 Impact factor: 2.563

Review 7. Growth hormone axis in chronic kidney disease.

Authors: Shefali Mahesh; Frederick Kaskel
Journal: Pediatr Nephrol Date: 2007-08-05 Impact factor: 3.714

Review 8. Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.

Authors: Yu-Shuan Chen; Zhen-Xiang Hong; Shinn-Zong Lin; Horng-Jyh Harn
Journal: Int J Mol Sci Date: 2020-04-26 Impact factor: 5.923

9. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors: Danilo Fintini; Claudia Brufani; Marco Cappa
Journal: Ther Clin Risk Manag Date: 2009-08-03 Impact factor: 2.423

Review 10. Growth retardation in children with kidney disease.

Authors: Paulina Salas; Viola Pinto; Josefina Rodriguez; Maria Jose Zambrano; Veronica Mericq
Journal: Int J Endocrinol Date: 2013-09-25 Impact factor: 3.257